Global Anaplastic Thyroid Cancer Drugs Market 2019-2023 | Presence of Reimbursement Policies for Chemotherapy to Boost the Market | Technavio

LONDON–(BUSINESS WIRE)–#Biotechnology–The global anaplastic thyroid cancer drugs market is expected to post a
CAGR of more than 4% during the period 2019-2023, according to the
latest market research report by Technavio.

Most of the available off-label therapies, such as chemotherapies have
adverse effects, which reduce patient adherence to the treatment. As a
result, exhaustive research has been carried out to develop targeted
therapies such as B-Rapidly Accelerated Fibrosarcoma (BRAF) kinase
inhibitors which are believed to be a suitable solution for cancer
treatment owing to their proven efficacy. Targeted therapies have
emerged as a prevailing class of therapeutics, acting through the
regulation of specific proteins and protein targets. The growing R&D in
this space and positive clinical trial results of late-stage molecules
is expected to fuel the growth of the global anaplastic thyroid cancer
drugs market.

As per Technavio, the presence of reimbursement policies for
chemotherapy will have a positive impact on the market and contribute to
its growth significantly over the forecast period. This global
anaplastic thyroid cancer drugs market 2019-2023 research
report also analyzes other important trends and market drivers that will
affect market growth over 2019-2023.

Global anaplastic thyroid cancer drugs market:
Presence of reimbursement policies for chemotherapy

Chemotherapeutics such as doxorubicin, cisplatin, and paclitaxel are the
most commonly used off-label therapies for the treatment of anaplastic
thyroid cancer. However, the cost of these therapeutics is extremely
high, posing a major challenge for patients as well as the healthcare
system. Therefore, many governments and NGOs are providing financial
assistance and clinical assistance for the treatment of various cancer
indications, including metastatic conditions such as anaplastic thyroid
cancer. Such reimbursement policies encourage more patients to avail the
required treatment, resulting in a wider patient base. Therefore, the
presence of reimbursement policies for chemotherapy will positively
impact the anaplastic thyroid cancer drugs market growth during the
forecast period.

“Apart from the presence of reimbursement policies for chemotherapy,
other factors such as growing awareness about thyroid cancer, rising
geriatric population, and strong pipeline will have a significant impact
on the growth of the anaplastic thyroid cancer drugs market size during
the forecast period,” says a senior analyst at Technavio.

Global anaplastic thyroid cancer drugs market:
Segmentation analysis

This market research report segments the global anaplastic thyroid
cancer drugs market by product (chemotherapy, and novel therapy), and
geographic regions (North America, Europe, Asia, and ROW).

The North American region led the anaplastic thyroid cancer drugs market
in 2018, followed by Europe, Asia, and ROW, respectively. The growth of
the anaplastic thyroid cancer drugs market in North America can be
attributed to the increasing cases of thyroid cancer in the region, and
new research activities related to the establishment of innovative
treatment methods such as immunotherapy and targeted therapy.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report, such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

• Market ecosystem
• Market characteristics
• Market segmentation analysis

Market Sizing

• Market definition
• Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

• Regional comparison
• Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Competitive scenario

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at [email protected].

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com